alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
1

UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF COLUMBIA

PAUL E. JOZWIAK, )

)

Plaintiff, )

 )

v. ) Civil Action No. 23-00883 (UNA)

 )

)

DAVID C. BURY, )

 )

Defendant. )

MEMORANDUM OPINION

Plaintiff, appearing pro se, has filed a prolix complaint and an application to proceed in 

forma pauperis. The Court will grant the application and dismiss this action pursuant to 28 U.S.C. 

§ 1915(e)(2)(B) (requiring dismissal of a case upon a determination that the complaint is frivolous 

or fails to state a claim on which relief may be granted).

Plaintiff, a Wisconsin resident who previously resided in Arizona, has sued U.S. District 

Judge David C. Bury. The complaint, to the extent intelligible, arises from Defendant’s rulings in 

Plaintiff’s case filed in the U.S. District Court for the District of Arizona. See Compl., ECF No. 1

at 10 (“Bury Is Charged With Illegally Presiding Over And Dismissing The Plaintiff’s ERISA 

Case Due To His Violations Of State and/or Federal Codes Of Judicial Conduct, Civil And 

Constitutional Rights, COVID Orders, ERISA-Law With That Of Written Law!”). Plaintiff seeks 

monetary damages and injunctive relief. See id. at 47-49.

An “in forma pauperis complaint is properly dismissed as frivolous . . . if it is clear from 

the face of the pleading that the named defendant is absolutely immune from suit on the claims 

asserted.” Crisafi v. Holland, 655 F.2d 1305, 1308 (D.C. Cir. 1981). It is established that judges 
2

enjoy absolute immunity from suits for damages based, as here, on their rulings in a judicial 

proceeding. See Caldwell v. Kagan, 777 F. Supp. 2d 177, 179 (D.D.C. 2011) (finding “claims 

against the district and court of appeals judges . . . patently frivolous because federal judges are 

absolutely immune from lawsuits predicated, as here, for their official acts”) (citing Forrester v. 

White, 484 U.S. 219, 225 (1988); Stump v. Sparkman, 435 U.S. 349, 355–57 (1978); Sindram v. 

Suda, 986 F.2d 1459, 1460 (D.C. Cir. 1993)); see also Fleming v. United States, 847 F. Supp. 170, 

172 (D.D.C. 1994), cert. denied, 513 U.S. 1150 (1995) (a complaint against judges who have “done 

nothing more than their duty” is “a meritless action.”). Moreover, a federal district court such as 

this “cannot review decisions of another district court,” Lu v. Eid, No. 21-5175, 2021 WL 6102201, 

at *1 (D.C. Cir. Nov. 29, 2021), and compel it to act. See United States v. Choi, 818 F. Supp. 2d 

79, 85 (D.D.C. 2011) (federal district courts “generally lack[ ] appellate jurisdiction over other 

judicial bodies, and cannot exercise appellate mandamus over other courts”). 

Because no “allegation of other facts” could plausibly cure the foregoing defects, the 

complaint is dismissed with prejudice. Firestone v. Firestone, 76 F.3d 1205, 1209 (D.C. Cir. 1996) 

(per curiam). A separate order accompanies this Memorandum Opinion.

 

 _________/s/___________

TANYA S. CHUTKAN

Date: April 14, 2023 United States District Judge
Exhibit 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Solely in connection with the filing of the Annual Report of Retractable Technologies, Inc. (the Company) on Form 10-K for the period ended
December 31, 2005, as filed with the United States Securities and Exchange Commission on the date hereof (the Report), the undersigned Thomas J. Shaw, Chief Executive Officer, and Douglas W. Cowan, Chief Financial Officer, do hereby
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The
Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information
contained in the Report as of the dates and for the periods covered by the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

March 31, 2006



/s/  THOMAS J. SHAWTHOMAS J. SHAWPRESIDENT, CHAIRMAN, ANDCHIEF EXECUTIVE OFFICER/s/  DOUGLAS W. COWANDOUGLAS W. COWANVICE PRESIDENT ANDCHIEF FINANCIAL OFFICER
#### John M. Wells *v.*Liquor Control Commission

*Stephen J. O’Neill,*assistant attorney general, for the appellee (defendant).

Argued March 4

decided March 4, 1969

It appearing that the plaintiff in the above-entitled case has failed to prosecute his appeal from the Court of Common Pleas in Hartford County with proper diligence, it is, under Practice Book § 696, ordered by the Supreme Court, suo motu, that the appeal be and hereby is dismissed.
<PAGE>

                                                                    EXHIBIT 99.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Home Products International, Inc.
(the "Company") on Form 10-Q for the period ended March 29, 2003 as filed with
the Securities and Exchange Commission on May 12, 2003, I, James E. Winslow,
Executive Vice President and Chief Financial Officer of the Company, certify,
pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the
Sarbanes-Oxley Act of 2002, that:

(1)  The Report fully complies with the requirements of section 13(a) or 15(d)
     of the Securities Exchange Act of 1934; and

(2)  The information contained in the Report fairly presents, in all material
     respects, the financial condition and results of operations of the Company.

/s/ JAMES E. WINSLOW
James E. Winslow
Executive Vice President and Chief Financial Officer
May 12, 2003

A signed original of this written statement required by Section 906 has been
provided to Home Products International, Inc. and will be retained by Home
Products International, Inc. and furnished to the Securities and Exchange
Commission or its staff upon request.
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.4340 Cardiopulmonary bypass level sensing monitor and/or control. ( a ) *Identification.* A cardiopulmonary bypass level sensing monitor and/or control is a device used to monitor and/or control the level of blood in the blood reservoir and to sound an alarm when the level falls below a predetermined value.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.
[45 FR 7907, Feb. 5, 1980, as amended at 84 FR 71812, Dec. 30, 2019]
§ 820.200 Servicing. ( a ) Where servicing is a specified requirement, each manufacturer shall establish and maintain instructions and procedures for performing and verifying that the servicing meets the specified requirements.
( b ) Each manufacturer shall analyze service reports with appropriate statistical methodology in accordance with § 820.100.
( c ) Each manufacturer who receives a service report that represents an event which must be reported to FDA under part 803 of this chapter shall automatically consider the report a complaint and shall process it in accordance with the requirements of § 820.198.
( d ) Service reports shall be documented and shall include: ( 1 ) The name of the device serviced;
( 2 ) Any unique device identifier (UDI) or universal product code (UPC), and any other device identification(s) and control number(s) used;
( 3 ) The date of service;
( 4 ) The individual(s) servicing the device;
( 5 ) The service performed; and
( 6 ) The test and inspection data.
[61 FR 52654, Oct. 7, 1996, as amended at 69 FR 11313, Mar. 10, 2004; 78 FR 58822, Sept. 24, 2013]
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1190 Copper test system. ( a ) *Identification.* A copper test system is a device intended to measure copper levels in plasma, serum, and urine. Measurements of copper are used in the diagnosis and treatment of anemia, infections, inflammations, and Wilson's disease (a hereditary disease primarily of the liver and nervous system). Test results are also used in monitoring patients with Hodgkin's disease (a disease primarily of the lymph system).
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
[52 FR 16122, May 1, 1987, as amended at 53 FR 21449, June 8, 1988; 66 FR 38787, July 25, 2001]
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.3980 Endosseous dental implant accessories. ( a ) *Identification.* Endosseous dental implant accessories are manually powered devices intended to aid in the placement or removal of endosseous dental implants and abutments, prepare the site for placement of endosseous dental implants or abutments, aid in the fitting of endosseous dental implants or abutments, aid in the fabrication of dental prosthetics, and be used as an accessory with endosseous dental implants when tissue contact will last less than 1 hour. These devices include drill bits, screwdrivers, countertorque devices, placement and removal tools, laboratory pieces used for fabrication of dental prosthetics, and trial abutments.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 872.9.
[65 FR 60099, Oct. 10, 2000]
<PAGE>   1
                                                                    EXHIBIT 23.2

               CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS

We consent to the incorporation by reference in the Registration Statement (Form
S-8), pertaining to the Ribi Immunochem Research, Inc. 1986 Stock Option Plan,
the Ribi Immunochem Research, Inc. 1996 Director Option Plan and the Ribi
Immunochem Research, Inc. 1996 Stock Option Plan of our report dated February
3, 1999 with respect to the consolidated financial statements of Corixa
Corporation included in its Annual Report on Form 10-K for the year ended
December 31, 1998, filed with the Securities and Exchange Commission.

                                                               ERNST & YOUNG LLP

Seattle, Washington
October, 21, 1999
Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration
 By Notice dated November 23, 2009, and published in the 
                    **Federal Register**
                     on December 2, 2009 (74 FR 63155), Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedule II: Drug
ScheduleOpium, raw (9600)
IIPoppy Straw Concentrate (9670)
II
 The company plans to import the basic classes of controlled substances for manufacture of active pharmaceutical ingredients for sale to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Cambrex Charles City, Inc. to import the basic classes of controlled substances is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Cambrex Charles City, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. Dated: February 26, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.


[FR Doc. 2010-4773 Filed 3-4-10; 8:45 am] BILLING CODE 4410-09-P
Michigan Supreme Court

Lansing, Michigan

Robert P. Young, Jr.

, Chief Justice

Michael F. Cavanagh

Stephen J. Markman

Mary Beth Kelly

Brian K. Zahra

Bridget M. McCormack

David F. Viviano

, Justices

I, Larry S. Royster , Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

July 21, 2014

jam 

# Order

Clerk July 21, 2014

1 49684 ( 29 )

RAYMOND E. CHASTAIN

,

Pla intiff

- Appellant,

v SC: 1 49684

COA: 320340

DEPARTMENT OF CORRECTIONS,

Defendant

- Appellee.

___________________________________

On order of the Chief Justice, the motion to waive fees is considered and it

is DENIED because MCL 600.2963 requires that a prisoner pursuing a civil action be

liable for filing fees.

Within 21 days of the certification of this order, plaintiff shall p ay to the

Clerk of the Court the initial partial filing fee of $7 8 .00, shall submit a copy of this order

with the payment, and shall refile the copy of the pleadings which is being returned

with this order. Failure to comply with this order shall result in the appeal not being

filed in this Court.

If plaintiff timely files the partial fee and refiles the pleadings, monthly

payments shall be made to the Department of Corrections in an amount of 50 percent of

the deposits made to plaintiff’s account until the payments equal the balance due of

$ 297 .00. This amount shall then be remitted to this Court.

Pursuant to MCL 600.2963(8) plaintiff shall not file further appeals in civil

actions in this Court until the entry fee in this case is paid in full.

The Clerk of the Court shall furnish two copies of this order to plaintiff and

return plaintiff’s pleadings with this order.
EXHIBIT 23.3

CONSENT OF INDEPENDENT ACCOUNTANTS

We hereby consent to the use in this Registration  Statement on Form S-4 of PSEG
Energy Holdings Inc. of our report dated March 3, 2000 relating to the financial
statements of Hanford L.P.,  which appears in such  Registration  Statement.  We
also  consent  to the  reference  to us  under  the  heading  "Experts"  in such
Registration Statement.

San Francisco, California                         /s/ PricewaterhouseCoopers LLP
July 10, 2000
Exhibit 32.2 

CERTIFICATION PURSUANTTO 

18 U.S.C.SECTION 1350, 

AS ADOPTED PURSUANT TO 

SECTION 906 OFTHE SARBANES-OXLEY ACT OF 2002 

        Inconnection with the accompanying Quarterly Report on Form 10-Q of Penn TreatyAmerican Corporation (the “Company”) for the period ended March 31, 2004 asfiled with the Securities and Exchange Commission, I, Cameron B. Waite, Executive VicePresident and Chief Financial Officer of****the Company**,** certify pursuant to 18U.S.C. Section §1350, as adopted pursuant to §906 of the Sarbanes-OxleyAct of 2002 that to the best of my knowledge:
# C_2015398EN.01007703.xml

| 30.11.2015 | EN | Official Journal of the European Union | C 398/77 |
| --- | --- | --- | --- |

30.11.2015

EN

Official Journal of the European Union

C 398/77

---

Order of the General Court of 14 October 2015 — Montenegro v OHIM (Shape of a bottle)

(Case T-748/14) (1)

1

(2015/C 398/91)

Language of the case: English

The President of the Eighth Chamber has ordered that the case be removed from the register.

---

(1)  OJ C 7, 12.1.2015.

1

---
EXHIBIT 11 - CALCULATION OF NET INCOME (LOSS) PER COMMON SHARE


                                  MICROAGE, INC
                 NET INCOME (LOSS) PER COMMON SHARE CALCULATION
                                 (in thousands)


<TABLE>
<CAPTION>
                                                                Quarter ended         26 weeks ended
                                                            --------------------   --------------------
                                                             May 3,      May 4,     May 3,      May 4,
                                                              1998        1997       1998        1997
                                                            --------    --------   --------    --------
<S>                                                           <C>         <C>        <C>         <C>   
Basic
     Weighted average common shares                           19,584      17,336     19,520      17,255
                                                            --------    --------   --------    --------

Diluted
     Weighted average shares from primary
          calculation                                         19,584      17,336     19,520      17,255

     Dilutive effect of stock options and warrants              --           540       --           806


                                                            --------    --------   --------    --------
          Weighted average common and common
            equivalent shares outstanding - diluted           19,584      17,876     19,520      18,061
                                                            --------    --------   --------    --------

Net income  (loss)                                          $ (5,255)   $  6,567   $(10,669)   $ 11,604

Net income (loss) per common and common equivalent share:
     Basic                                                  $  (0.27)   $   0.38   $  (0.54)   $   0.67
                                                            ========    ========   ========    ========
     Diluted                                                $  (0.27)   $   0.37   $  (0.54)   $   0.64
                                                            ========    ========   ========    ========
</TABLE>
|   | 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------|

|   | 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Date:  |        May 16, 2011 |   |  By: | /s/ Edward P. Smolyansky                                                                     |   |
|--------|---------------------------------------------------|--------|-----------|----------------------------------------------------------------------------------------------|--------|
|   |                                              |   |      | Edward P. SmolyanskyChief Financial and Accounting Officer and Treasurer |   |
Exhibit
10.18


 


[IHI Letterhead]


 


 


January 29, 2003


 


Mr. Fenton Markevich


President & CEO


CRC Press LLC


2000 Corporate Blvd. N.W.


Boca Raton, Florida 33431


 


Re:      Transaction Bonus


 


Dear Mr. Markevich:


 


This letter agreement sets forth the bonus
that you will be eligible to receive if a sale of all or substantially all of
the capital stock or assets of CRC Press LLC (the “Company”) by Information
Holdings Inc. or an affiliate (“IHI”) to Taylor & Francis Group plc
(“T&F”) is completed within six months of the date hereof (a “Sale”).  All amounts payable to you under this bonus
arrangement will be in addition to, not in lieu of, any and all amounts to
which you are entitled, or may become entitled with respect to your stock
option grants, and any other compensation or benefits payable under any IHI or
Company plan.


 


In the event a Sale occurs, and provided that
you have remained in the continuous employ of the Company from the date of this
letter agreement until the closing date of such Sale (the “Closing Date”), you
will receive, on the Closing Date, a lump sum bonus payment of $200,000.  All amounts payable to you pursuant to the
terms of this letter agreement shall be subject to withholding for all
applicable federal, state and local withholding taxes.


 


You also acknowledge that, provided you
obtain an employment agreement with T&F, IHI shall have no obligation to
provide you severance or related payments resulting from the termination of
your employment with the Company on the Closing Date.


 

















 


Please indicate your acceptance of the terms
of this letter agreement by signing and dating this letter in the space
indicated below.


 


Sincerely,


 


	
  INFORMATION HOLDINGS INC.

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ Mason P. Slaine

  	
   

  	
   

  
	
   

  	
  Mason P. Slaine

  	
   

  
	
   

  	
  Chief Executive Officer

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Fenton Markevich

  	
   

  	
   

  
	
   

  	
  Fenton Markevich

  	
   

  



 


2
<PAGE>

                                   Exhibit 11

                 STATEMENT RE: COMPUTATION OF PER SHARE EARNINGS
                  (amounts in thousands, except per share data)
                                   (unaudited)


 
<TABLE>
<CAPTION>
                                                       Three Months Ended
                                                           March 31,
                                                      --------------------
                                                        1998       1997
                                                      ---------  ---------
<S>                                                   <C>        <C>
Net income                                            $   8,371  $   3,419
Weighted average common shares outstanding                7,572      7,516
Basic earnings per share                              $    1.11  $    0.45
                                                      ---------  ---------
                                                      ---------  ---------
Net income                                            $   8,371  $   3,419
Adjustments net of tax:
  Interest expense on convertible debt                      773        829
  Amortization of debt offering costs                        60         64
                                                      ---------  ---------
Diluted net income                                    $   9,204  $   4,312
                                                      ---------  ---------
                                                      ---------  ---------
Weighted average common shares outstanding                7,572      7,516
Common stock equivalents due to dilutive effect of
  stock options                                             218        196
Shares converted from convertible debt                    2,628      2,628
                                                      ---------  ---------
Total outstanding shares for diluted earnings per
  share computation                                      10,418     10,340
Diluted earnings per share                            $    0.88  $    0.42
                                                      ---------  ---------
                                                      ---------  ---------
</TABLE>




                                       15